GlassScriptPhysician profile
John Charles Kunesh
NPI 1083792287
$1,270.50
in general payments reported to CMS, 2019-2025
12 companies · $190 in 2025
The $190 reported for 2025 was less than what a typical Ophthalmic Plastic and Reconstructive Surgery provider received nationally (typical 2025 total: $299).
See the full distribution for Ophthalmic Plastic and Reconstructive Surgery
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $146 · 2021: $132 · 2022: $35.34 · 2023: $451 · 2024: $316 · 2025: $190.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $939 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $939.14 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $330.13 | 2024-2025 | Istent Trabecular Micro-Bypass System Model Is3, Idosetr |
| Abbvie INC. | $234.01 | 2022-2025 | |
| Apellis Pharmaceuticals, INC. | $123.06 | 2023 | Syfovre |
| Allergan, INC. | $116.70 | 2020-2021 | |
| Alcon Vision LLC | $98.87 | 2020-2025 | Clareon, Argos |
| Genentech USA, INC. | $88.52 | 2023-2025 | Vabysmo |
| Horizon Therapeutics Plc | $80.20 | 2021-2022 | |
| Astellas Pharma US INC | $69.46 | 2023 | Izervay |
| Carl Zeiss Meditec, INC. | $50.00 | 2020 | |
| Biotissue Holdings INC. | $49.77 | 2023 | |
| Bausch & Lomb Americas INC. | $17.84 | 2023 | Miebo |
| Kala Pharmaceuticals, INC. | $11.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Kunesh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.